Mourad Tayebi, PhD, Western Sydney University in Penrith, Australia, emphasizes the importance of antibody selectivity when developing future therapeutics for Alzheimer’s disease. Over the past decade, significant progress has been made in understanding the complex nature of amyloid-beta (Aβ) assemblies and the role of oligomeric species in neurotoxicity. The Tayebi lab are working to develop novel antibodies effective in selectively binding to soluble oligomeric species, in an effort to improve the safety and efficacy profiles of next-generation anti-amyloid immunotherapies. By shedding light on the intricate nature of Aβ and developing targeted interventions, Dr Tayebi’s work contributes to the advancement of new biologics for Alzheimer’s disease and other proteinopathies. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
